A Post-approval Study of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System

Trial Profile

A Post-approval Study of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Ischaemia; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ONYX PAS
  • Sponsors Medtronic
  • Most Recent Events

    • 04 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 27 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top